ZNF224 and chronic myelogenous leukemia, BCR-ABL1 positive: These findings strongly suggest that the induction of ZNF224 expression, by targeting signaling pathways downstream of Bcr-Abl, may be exploited as basis for the development of new therapeutic approach in imatinib-resistant CML.